BPC-157

BPC-157 is a synthetic pentadecapeptide composed of 15 amino acids, originally derived from a fragment of a body protection compound found in human gastric juice, which inspired its name. It is a partial sequence rather than a complete naturally occurring protein, and therefore it does not correspond to a single UniProt entry.

In preclinical research, BPC-157 has attracted significant attention due to its reported stability and broad, or pleiotropic, activity across multiple tissue types. Laboratory and animal studies have primarily focused on its potential to promote tissue repair and regeneration.

Researchers investigate BPC-157 for its ability to accelerate healing in various soft tissues, including tendons, ligaments, skeletal muscle, and the gastrointestinal tract, reflecting its origin from gastric juice. It is strictly designated for laboratory and research use only and is not approved for clinical use by regulatory authorities.

The 2025 review titled "Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review" summarizes BPC-157’s pleiotropic beneficial effects demonstrated in various preclinical models, including tissue injury, inflammatory bowel disease, and central nervous system disorders. It notes a desirable safety profile with few reported side effects but highlights the lack of FDA approval and comprehensive clinical studies in humans. The review also discusses the peptide’s patent landscape and the implications of its availability on the market despite regulatory restrictions.

The 2019 study "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing" critically reviews preclinical literature focusing on BPC-157’s capacity to promote healing and functional restoration in tendons, ligaments, and skeletal muscle. The authors emphasize consistent positive outcomes in animal models but acknowledge that most research has been conducted in rodents and that human efficacy remains to be established. They highlight the peptide’s potential to address hypovascular and hypocellular soft tissue injuries.

In the 2025 systematic review "Emerging Use of BPC-157 in Orthopaedic Sports Medicine," the authors analyze 36 studies from 1993 to 2024. Findings indicate that BPC-157 promotes healing via growth factor enhancement and inflammation reduction in muscle, tendon, ligament, and bone injury models. One human study reported symptom relief in chronic knee pain after BPC-157 injection, but clinical safety data remain absent. The review underscores the peptide’s therapeutic promise alongside concerns about unregulated production and the need for further clinical investigation.

Within the preclinical research literature, dosing protocols for BPC-157 vary depending on the experimental model, route of administration, and targeted tissue. Studies often employ systemic or local administration in animal models, with doses calibrated to achieve tissue healing effects. However, precise dosing ranges are not well standardized due to variability in study designs and species differences.

Human dosing parameters have not been established in controlled clinical trials, and reported use in investigational or anecdotal contexts lacks rigorous validation. Consequently, dosing information remains limited to preclinical research settings, emphasizing the need for further systematic investigation to define safe and effective dosage protocols.